Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Plasminogen activators and their potential in therapy.

I J Hollander1

  • 1Immunoinflammatory Diseases Research, G. D. Searle Research and Development, Monsanto Life Sciences Research Center, St. Louis, Missouri.

Critical Reviews in Biotechnology
|January 1, 1987
PubMed
Summary

Tissue plasminogen activator (t-PA) offers specific clot lysis, unlike older plasminogen activators (PAs) like urokinase and streptokinase which cause systemic side effects. Research reviews t-PA

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785).

Biochemical pharmacology·1999
Same author

Calicheamicin derivatives conjugated to monoclonal antibodies: determination of loading values and distributions by infrared and UV matrix-assisted laser desorption/ionization mass spectrometry and electrospray ionization mass spectrometry.

Analytical chemistry·1997
Same author

Adenomyoepithelioma of the breast. A spectrum of biologic behavior.

The American journal of surgical pathology·1992
Same author

Matrix-assisted UV-laser desorption/ionization mass spectrometric analysis of monoclonal antibodies for the determination of carbohydrate, conjugated chelator, and conjugated drug content.

Analytical chemistry·1991
Same author

Normal ranges and "errors".

Annals of internal medicine·1989
Same author

A pure enzyme catalyzing penicillin biosynthesis.

Science (New York, N.Y.)·1984

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Plasminogen activators (PAs) are crucial enzymes in fibrinolysis, converting plasminogen to plasmin for clot dissolution.
  • Existing therapeutic PAs, urokinase (UK) and streptokinase (SK), are associated with systemic fibrinogenolysis and adverse effects.
  • Tissue plasminogen activator (t-PA) is a novel PA investigated for targeted clot lysis with fewer systemic complications.

Purpose of the Study:

  • To review the properties and therapeutic potential of tissue plasminogen activator (t-PA).
  • To compare t-PA with emerging activators, such as pro-urokinase.
  • To discuss the influence of PA-inhibitor interactions on therapeutic applications.

Main Methods:

  • Literature review of existing studies on plasminogen activators.
  • Comparative analysis of t-PA, urokinase, streptokinase, and pro-urokinase.
  • Discussion of the role of inhibitors in plasminogen activator therapy.

Main Results:

  • Tissue plasminogen activator (t-PA) demonstrates specific clot lysis, minimizing systemic side effects.
  • The gene for t-PA has been successfully cloned, paving the way for biotechnological production.
  • Newer forms of activators, like pro-urokinase, are being developed alongside t-PA.

Conclusions:

  • Tissue plasminogen activator (t-PA) presents a promising therapeutic option for fibrinolysis due to its specificity.
  • Understanding PA-inhibitor interactions is vital for optimizing fibrinolytic therapies.
  • Advancements in biotechnology are enabling the production and potential clinical use of t-PA.

Related Experiment Videos